Baseline radiological tumor burden to sub-stratify IMDC risk groups in metastatic renal cell carcinoma treated with first-line therapy: A post hoc analysis from a randomized phase III trial.
Nawfal R, El Hajj Chehade R, Semaan K, Eid M, Ascione L, Saad E, Daoud Khatoun W, Jamal Saleh M, El Masri J, Xu W, Yekeduz E, Sun M, Braun D, Gupta S, Heng D, Krajewski K, Choueiri T. Baseline radiological tumor burden to sub-stratify IMDC risk groups in metastatic renal cell carcinoma treated with first-line therapy: A post hoc analysis from a randomized phase III trial. Journal Of Clinical Oncology 2025, 43: 4544-4544. DOI: 10.1200/jco.2025.43.16_suppl.4544.Peer-Reviewed Original ResearchProgression-free survivalMetastatic renal cell carcinomaIMDC risk groupsPoor-risk groupAssociated with OSOverall survivalTumor burdenRisk groupsMultivariate analysisRandomized prospective phase III studyProgression-free survival eventsProspective phase III studyAssociated with worse OSRandomized phase III trialMultivariate Cox regression modelBaseline tumor burdenCheckMate 9ER trialPoor-risk subgroupsFavorable risk groupRoutine CT scansFirst-line therapyPhase III studyIntermediate risk groupPhase III trialsRenal cell carcinoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply